» Articles » PMID: 39015025

RGS1 and CREB5 Are Direct and Common Transcriptional Targets of ZNF384-fusion Proteins

Overview
Journal Cancer Med
Specialty Oncology
Date 2024 Jul 17
PMID 39015025
Authors
Affiliations
Soon will be listed here.
Abstract

Background: ZNF384-fusion (Z-fusion) genes were recently identified in B-cell acute lymphoblastic leukemia (B-ALL) and are frequent in Japanese adult patients. The frequency is about 20% in those with Philadelphia chromosome-negative B-ALL. ZNF384 is a transcription factor and Z-fusion proteins have increased transcriptional activity; however, the detailed mechanisms of leukemogenesis of Z-fusion proteins have yet to be clarified.

Methods: We established three transfectants of cell lines expressing different types of Z-fusion proteins, and analyzed their gene expression profile (GEP) by RNA-seq. We also analyzed the GEP of clinical ALL samples using our previous RNA-seq data of 323 Japanese ALL patients. We selected upregulated genes in both Z-fusion gene-expressing transfectants and Z-fusion gene-positive ALL samples, and investigated the binding of Z-fusion proteins to regulatory regions of the candidate genes by ChIP-qPCR.

Results: We selected six commonly upregulated genes. After the investigation by ChIP-qPCR, we finally identified CREB5 and RGS1 as direct and common target genes. RGS1 is an inhibitor of CXCL12-CXCR4 signaling that is required for the homing of hematopoietic progenitor cells to the bone marrow microenvironment and development of B cells. Consistent with this, Z-fusion gene transfectants showed impaired migration toward CXCL12.

Conclusions: We identified CREB5 and RGS1 as direct and common transcriptional targets of Z-fusion proteins. The present results provide novel insight into the aberrant transcriptional regulation by Z-fusion proteins.

Citing Articles

RGS1 and CREB5 are direct and common transcriptional targets of ZNF384-fusion proteins.

Yamada C, Okada K, Odaira K, Tokoro M, Iwamoto E, Sanada M Cancer Med. 2024; 13(14):e7471.

PMID: 39015025 PMC: 11252495. DOI: 10.1002/cam4.7471.

References
1.
Burger J, Burkle A . The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007; 137(4):288-96. DOI: 10.1111/j.1365-2141.2007.06590.x. View

2.
He S, Deng Y, Liao Y, Li X, Liu J, Yao S . CREB5 promotes tumor cell invasion and correlates with poor prognosis in epithelial ovarian cancer. Oncol Lett. 2017; 14(6):8156-8161. PMC: 5727587. DOI: 10.3892/ol.2017.7234. View

3.
Thunyakitpisal P, Alvarez M, Tokunaga K, Onyia J, Hock J, Ohashi N . Cloning and functional analysis of a family of nuclear matrix transcription factors (NP/NMP4) that regulate type I collagen expression in osteoblasts. J Bone Miner Res. 2001; 16(1):10-23. DOI: 10.1359/jbmr.2001.16.1.10. View

4.
Wang S, Qiu J, Liu L, Su C, Qi L, Huang C . CREB5 promotes invasiveness and metastasis in colorectal cancer by directly activating MET. J Exp Clin Cancer Res. 2020; 39(1):168. PMC: 7446182. DOI: 10.1186/s13046-020-01673-0. View

5.
Li J, Dai Y, Lilljebjorn H, Shen S, Cui B, Bai L . Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A. 2018; 115(50):E11711-E11720. PMC: 6294900. DOI: 10.1073/pnas.1814397115. View